2026 James A. Johnston: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	59	12538	11541	5366	4812	134	12444

Overview

James A. Johnston is affiliated with ImmPACT Bio in the United States. Their research spans the fields of Immunology and Microbiology, Medicine, and Biochemistry, Genetics, and Molecular Biology. The scientist's work predominantly focuses on subfields including Immunology, Oncology, and Molecular Biology.

The main topics of their research include:

Immunotherapy and Immune Responses
Vaccines and Immunoinformatics Approaches
Cancer Immunotherapy and Biomarkers
Ubiquitin and Proteasome Pathways
CAR-T Cell Therapy Research
Peptidase Inhibition and Analysis
Immune Cell Function and Interaction

Recent publications by James A. Johnston cover a variety of subjects related to immunotherapy and protein degradation pathways. Selected papers include:

A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses, 2020, npj Vaccines
Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation, 2023, Science Advances
HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease, 2020, Cytotherapy
A Systematic Interrogation of MHC Class I Peptide Presentation Identifies Constitutive and Compensatory Protein Degradation Pathways, 2021, bioRxiv (Cold Spring Harbor Laboratory)
Listeria monocytogenes personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens, 2020, bioRxiv (Cold Spring Harbor Laboratory)

James A. Johnston often collaborates with peers in their field. Frequent coauthors include:

J. Russell Lipford
Bryan Vander Lugt
Hyewon Phee
Jennifer L. Mamrosh
David J. Sherman

Their work has been published in venues such as:

bioRxiv (Cold Spring Harbor Laboratory)
npj Vaccines
Science Advances
Cytotherapy

Best Publications

Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3 : implications for XSCID and XCID

Sarah M. Russell;James A. Johnston;Masayuki Noguchi;Masaru Kawamura

836
Citations
Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2

James A. Johnston;Masaru Kawamura;Robert A. Kirken;Yi Qing Chen

757
Citations
Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes.

Chris M. Bacon;Emanuel F. Petricoin;John R. Ortaldo;Robert C. Rees

579
Citations
SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses

Yoh Ichi Seki;Hiromasa Inoue;Naoko Nagata;Katsuhiko Hayashi

530
Citations
Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.

Atsuo Sasaki;Hideo Yasukawa;Asuka Suzuki;Shintaro Kamizono

523
Citations
Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12.

Chris M. Bacon;Daniel W. McVicar;John R. Ortaldo;Robert C. Rees

450
Citations
SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation.

Solomon J. Cohney;David Sanden;Nicholas A. Cacalano;Akihiko Yoshimura

379
Citations
Lipopolysaccharide Induces in Macrophages the Synthesis of the Suppressor of Cytokine Signaling 3 and Suppresses Signal Transduction in Response to the Activating Factor IFN-γ

Dagmar Stoiber;Pavel Kovarik;Solomon Cohney;James A. Johnston

323
Citations
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

John R. Teerlink;John R. Teerlink;G. Michael Felker;John J. V. McMurray;Scott D. Solomon

315
Citations
Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras.

Nicholas A. Cacalano;David Sanden;James A. Johnston

297
Citations
Signaling by Type I and II cytokine receptors: ten years after

Massimo Gadina;Douglas Hilton;James A Johnston;Akio Morinobu

286
Citations
Chemokines and serpentines: the molecular biology of chemokine receptors.

David J. Kelvin;Dennis F. Michiel;James A. Johnston;Andrew R. Lloyd

251
Citations
Respiratory Syncytial Virus NS1 Protein Degrades STAT2 by Using the Elongin-Cullin E3 Ligase

Joanne Elliott;Oonagh T. Lynch;Yvonne Suessmuth;Ping Qian

239
Citations
Structural and functional basis for JAK3-deficient severe combined immunodeficiency.

Fabio Candotti;Scott A. Oakes;James A. Johnston;Silvia Giliani

216
Citations
SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation.

Gillian M. Tannahill;Joanne Elliott;Anna C. Barry;Linda Hibbert

197
Citations
Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

Anne Rascle;James A. Johnston;Bruno Amati

196
Citations
Interleukins 2, 4, 7, and 15 Stimulate Tyrosine Phosphorylation of Insulin Receptor Substrates 1 and 2 in T Cells POTENTIAL ROLE OF JAK KINASES

James A. Johnston;Ling-Mei Wang;Eric P. Hanson;Xiao-Jian Sun

190
Citations
Suppressor of Cytokine Signaling-3 Is Recruited to the Activated Granulocyte-Colony Stimulating Factor Receptor and Modulates its Signal Transduction

Michael Hörtner;Ulrich Nielsch;Lorenz M. Mayr;James A. Johnston

184
Citations
Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7.

Tiziana Musso;James A. Johnston;Diana Linnekin;Luigi Varesio

183
Citations
SOCS: role in inflammation, allergy and homeostasis

Joanne Elliott;James A Johnston

177
Citations